M&T Bank Corp Boosts Holdings in IDEXX Laboratories, Inc. $IDXX

Key Points

• M&T Bank raised its stake in IDEXX by 70.1% in Q4 to 5,982 shares worth $4.05 million, part of a broader institutional ownership level of about 87.84%.
• IDEXX beat Q1 estimates on EPS ($3.47) and revenue ($1.14B) and raised FY‑2026 guidance to $14.45–$14.90 EPS and $4.7B–$4.8B in revenue, with double‑digit Companion Animal growth and margin expansion (net margin ~24.6%).
• Despite strong results, the stock trades at a rich P/E (~42.7), several analysts have trimmed targets and insiders recently sold ~45,957 shares (~$29.9M), raising valuation and timing concerns even as the consensus is a "Moderate Buy."

M&T Bank Corp increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 70.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,982 shares of the company's stock after buying an additional 2,465 shares during the period. M&T Bank Corp's holdings in IDEXX Laboratories were worth $4,047,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Virtus Advisers LLC purchased a new stake in IDEXX Laboratories during the third quarter worth about $26,000. Park Place Capital Corp bought a new position in IDEXX Laboratories during the fourth quarter worth about $29,000. WealthCollab LLC bought a new position in IDEXX Laboratories during the second quarter worth about $30,000. J.Safra Asset Management Corp bought a new position in IDEXX Laboratories during the third quarter worth about $31,000. Finally, Greykasell Wealth Strategies Inc. bought a new position in IDEXX Laboratories during the third quarter worth about $35,000. Hedge funds and other institutional investors own 87.84% of the company's stock.

Key IDEXX Laboratories News

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Q1 beat on both EPS and revenue — IDXX reported $3.47 EPS (above consensus) and $1.141B in revenue, driven by double‑digit growth in its Companion Animal Group and 11% organic revenue growth; the core business momentum is the primary near‑term catalyst. IDEXX Laboratories Announces First-Quarter Results
• Positive Sentiment: Management raised FY‑2026 guidance — IDXX set EPS guidance of $14.45–$14.90 and revenue guidance of $4.7B–$4.8B while signaling continued diagnostic innovation and service growth, which supports the stock’s upside narrative. IDEXX Laboratories Lifts Guidance on Robust Q1
• Positive Sentiment: Margin expansion and profitability metrics improved — net margin (~24.6%) and strong ROE reflect operating leverage from higher-margin diagnostics and service mix, which helps translate revenue growth into EPS upside. IDEXX Stock Up on Q1 Earnings & Revenue Beat, Margins Rise, '26 View Up
• Neutral Sentiment: Detailed commentary and slides available — the earnings call transcript and presentation provide color on geographic trends, product cadence and M&A posture; useful for investors digging into sustainability of growth and margin assumptions. IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Valuation and recent run raise timing questions — some analysts/commentary note IDXX has rallied significantly over the past year and trades at a rich P/E, leading to debate whether upside is already priced in and whether the guidance is materially better than street expectations. Is It Too Late To Consider IDEXX Laboratories (IDXX) After Its 18.5% One-Year Rally?

IDEXX Laboratories Price Performance

IDXX stock opened at $579.23 on Thursday. The firm has a 50 day moving average of $587.21 and a 200-day moving average of $650.39. The company has a current ratio of 1.12, a quick ratio of 0.90 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12 month low of $471.74 and a 12 month high of $769.98. The firm has a market capitalization of $46.01 billion, a P/E ratio of 42.65, a price-to-earnings-growth ratio of 3.41 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating analysts' consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same period last year, the business earned $2.91 earnings per share. IDEXX Laboratories's revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 14.58 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP George Fennell sold 11,345 shares of the firm's stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total value of $7,337,038.40. Following the completion of the transaction, the executive vice president directly owned 9,823 shares in the company, valued at approximately $6,352,730.56. This trade represents a 53.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael G. Erickson sold 5,371 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the completion of the transaction, the executive vice president owned 12,693 shares of the company's stock, valued at $7,963,334.34. This trade represents a 29.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 45,957 shares of company stock valued at $29,862,109 in the last three months. Insiders own 0.79% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Stifel Nicolaus cut their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a "buy" rating for the company in a research report on Tuesday, March 31st. UBS Group cut their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a "neutral" rating for the company in a research report on Tuesday, April 28th. Barclays cut their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating for the company in a research report on Thursday, February 5th. Piper Sandler cut their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating for the company in a research report on Monday, February 9th. Finally, Citigroup assumed coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a "neutral" rating and a $650.00 target price for the company. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.